Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem ...

Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) at the 2025 Alpha-1 ...

First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam’s Second Clinical Stage In Vivo Editing Program Updated Data from BEACON Phase 1/2 Clinical Trial of ...

We expect investors to focus on Beam Therapeutics’ BEAM progress in developing its pipeline candidates, which are being studied for hematological and immuno-oncology indications, when it reports first ...

Beam Therapeutics (NASDAQ:BEAM) outlined a new liver-targeted development program for phenylketonuria (PKU) and announced a ...

During the last three months, 4 analysts shared their evaluations of Beam Therapeutics (NASDAQ:BEAM), revealing diverse outlooks from bullish to bearish. The following table encapsulates their recent ...

Beam, which is still in the clinical stage, earned slightly under $7.5 million in its first quarter of the year on license and collaboration revenue. That was largely flat year over year. With an ...

The latest announcement is out from Beam Therapeutics ( (BEAM)). On December 8, 2025, Bristol-Myers Squibb completed its acquisition of Orbital Therapeutics, in which Beam Therapeutics held a 17% ...

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best gene-editing stocks to buy according to hedge funds. On November 14, Beam Therapeutics Inc. (NASDAQ:BEAM) announced Q3 2025 results in which it ...